drugset / Trial / NCT02070965

DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

NCT02070965

Phase 2 Completed 75 enrolled Primus Pharmaceuticals Prosoft Clinical · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the potential of DFD01 spray to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to Comp01 lotion when applied twice daily for 15 days.

Timeline

Start
2014-01
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Comp01 Unknown 0.05 %
Subject betamethasone dipropionate Small molecule 0.05 % Topical

Indications